UK markets close in 19 minutes
  • FTSE 100

    7,584.30
    +20.75 (+0.27%)
     
  • FTSE 250

    22,645.44
    -7.27 (-0.03%)
     
  • AIM

    1,150.96
    -3.24 (-0.28%)
     
  • GBP/EUR

    1.2014
    +0.0012 (+0.10%)
     
  • GBP/USD

    1.3630
    +0.0031 (+0.23%)
     
  • BTC-GBP

    30,760.00
    +123.00 (+0.40%)
     
  • CMC Crypto 200

    996.56
    +1.81 (+0.18%)
     
  • S&P 500

    4,572.82
    -4.29 (-0.09%)
     
  • DOW

    35,307.34
    -61.13 (-0.17%)
     
  • CRUDE OIL

    87.22
    +1.79 (+2.10%)
     
  • GOLD FUTURES

    1,839.00
    +26.60 (+1.47%)
     
  • NIKKEI 225

    27,467.23
    -790.02 (-2.80%)
     
  • HANG SENG

    24,127.85
    +15.07 (+0.06%)
     
  • DAX

    15,799.59
    +27.03 (+0.17%)
     
  • CAC 40

    7,160.67
    +26.84 (+0.38%)
     

Global Biosimilar Hormones Market Report 2021: Market is Expected to Reach $5.35 Billion in 2025 at a CAGR of 25% - Long-term Forecast to 2030

·3-min read

Dublin, Dec. 21, 2021 (GLOBE NEWSWIRE) -- The "Biosimilar Hormones Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

The global biosimilar hormones market is expected to grow from $1.94 billion in 2020 to $2.19 billion in 2021 at a compound annual growth rate (CAGR) of 12.9%. The market is expected to reach $5.35 billion in 2025 at a CAGR of 25%.

Major players in the biosimilar hormones market are Teva Pharmaceutical, Gedeon Richter, Intas Pharmaceuticals, Biocon, Mylan, Sanofi, Sandoz (Novartis), LG Life Sciences, Ferring Pharmaceuticals, and GC Pharma.

The biosimilar hormones market consists of sales of biosimilar hormones by entities that engage in manufacturing biosimilar hormones. These hormones are used when patients have a drop in hormones in their bodies or are unbalanced. Only goods and services traded between entities or sold to end consumers are included.

Stringent regulations imposed on the approval of hormone biosimilars limits the growth of the biosimilar hormones market. Biosimilars are approved on the same standard of pharmaceutical quality, efficacy, and safety that apply to all biologics approved in the European Union. There should be a similarity between the biologics and biosimilars, and as the process of manufacturing differs, the approval process becomes expensive and likely hinders the growth of the biosimilar hormones market.

The prevalence of deficiencies in growth hormones and metabolic hormones contributes to the market. The treatments required for hormone-related conditions are evolving over the years and the prevalence of hormonal deficiencies is generating higher demand for the hormone biosimilars market.

For instance, according to the Italian Journal of Pediatrics, the prevalence of growth hormone deficiency (GHD) in childhood widely varies between 1 out of 3480 and 1 out of 30,000 children annually. In children, the growth hormone can influence bone mineralization and lead to several metabolic effects, including glucose and lipid homeostasis. Annually, about 6,000 adults are diagnosed with growth hormone (GH) deficiency in the USA. The growing need to treat patients with prevailing hormonal deficiencies drives the biosimilar hormones market.

Key players operating in the biosimilar hormones market are undertaking various strategic initiatives such as new product launch in untapped regions to make the drug accessible to a large population. The companies are focusing on launching their products across various locations to boost sales and maximize profits.

Key Topics Covered:

1. Executive Summary

2. Biosimilar Hormones Market Characteristics

3. Biosimilar Hormones Market Trends and Strategies

4. Impact Of COVID-19 On Biosimilar Hormones

5. Biosimilar Hormones Market Size and Growth
5.1. Global Biosimilar Hormones Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Biosimilar Hormones Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market

6. Biosimilar Hormones Market Segmentation
6.1. Global Biosimilar Hormones Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Teriparatide Biosimilars

  • Follitropin Alfa Biosimilars

  • Insulin Biosimilars

  • Somatropin Biosimilars

  • Others

6.2. Global Biosimilar Hormones Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Research & biotechnology

  • Diagnostics

  • Biocatalysts

  • Therapeutics

  • Others

6.3. Global Biosimilar Hormones Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Hospital and Retail Pharmacy

  • Online Pharmacy/ePharmacy

  • Speciality Clinics

7. Biosimilar Hormones Market Regional and Country Analysis
7.1. Global Biosimilar Hormones Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Biosimilar Hormones Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentione

  • Teva Pharmaceutical

  • Gedeon Richter

  • Intas Pharmaceuticals

  • Biocon

  • Mylan

  • Sanofi

  • Sandoz (Novartis)

  • LG Life Sciences

  • Ferring Pharmaceuticals

  • GC Pharma

For more information about this report visit https://www.researchandmarkets.com/r/r2cmr6

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting